Bioventus Inc. (NYSE:BVS) Shares Bought by Franklin Resources Inc.

Franklin Resources Inc. boosted its stake in shares of Bioventus Inc. (NYSE:BVS - Free Report) by 56.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 126,140 shares of the company's stock after acquiring an additional 45,728 shares during the period. Franklin Resources Inc. owned about 0.16% of Bioventus worth $1,324,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. JPMorgan Chase & Co. grew its holdings in shares of Bioventus by 228.3% during the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company's stock worth $3,032,000 after buying an additional 176,442 shares in the last quarter. State Street Corp raised its holdings in Bioventus by 38.8% in the 3rd quarter. State Street Corp now owns 676,501 shares of the company's stock valued at $8,084,000 after acquiring an additional 189,216 shares during the last quarter. Barclays PLC lifted its stake in Bioventus by 24.2% in the 3rd quarter. Barclays PLC now owns 50,654 shares of the company's stock worth $606,000 after purchasing an additional 9,854 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Bioventus by 7.5% in the third quarter. Geode Capital Management LLC now owns 940,496 shares of the company's stock valued at $11,241,000 after purchasing an additional 65,374 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Bioventus by 11.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 435,344 shares of the company's stock worth $4,571,000 after buying an additional 45,182 shares in the last quarter. 62.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $15.00 target price on shares of Bioventus in a research note on Monday, March 17th.

Bioventus Trading Up 0.5 %

BVS traded up $0.04 during trading hours on Friday, reaching $7.82. The company's stock had a trading volume of 323,591 shares, compared to its average volume of 446,547. The business's 50-day moving average is $9.29 and its 200-day moving average is $10.60. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock has a market cap of $640.80 million, a PE ratio of -12.82 and a beta of 0.92. Bioventus Inc. has a fifty-two week low of $3.90 and a fifty-two week high of $14.38.

Insider Transactions at Bioventus

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the company's stock in a transaction that occurred on Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the transaction, the chief financial officer now directly owns 141,088 shares in the company, valued at approximately $1,068,036.16. This represents a 2.67 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the sale, the senior vice president now owns 118,178 shares of the company's stock, valued at $1,204,233.82. This trade represents a 3.57 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 24,208 shares of company stock worth $226,138. 32.90% of the stock is currently owned by company insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.